{"id":817508,"date":"2025-02-25T08:16:07","date_gmt":"2025-02-25T13:16:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\/"},"modified":"2025-02-25T08:16:07","modified_gmt":"2025-02-25T13:16:07","slug":"palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\/","title":{"rendered":"Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference"},"content":{"rendered":"
\n

WAYNE, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc.<\/a> (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that its management team will present at the TD Cowen 45th\u00a0Annual Healthcare Conference on Tuesday March 4, 2025, at 2:30 p.m. ET.<\/p>\n

A live webcast of the presentation will be available on the\u00a0Events and Presentations<\/a>\u00a0section of Palvella’s website at\u00a0www.palvellatx.com<\/a>. An archived replay of the webcast will be available for approximately 90 days following the presentation.<\/p>\n

\n About Palvella Therapeutics<\/strong>\n <\/p>\n

Founded and led by rare drug disease drug development veterans, Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN\u2122 platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella\u2019s lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN\u2122 rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit\u00a0www.palvellatx.com<\/a>\u00a0or follow Palvella on\u00a0LinkedIn<\/a>\u00a0or\u00a0X<\/a>\u00a0(formerly known as Twitter).<\/p>\n

QTORIN\u2122 rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency.<\/p>\n

\n Contact\u00a0Information<\/strong>\n <\/p>\n

\n Investors<\/u>
\n
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com<\/a><\/p>\n

\n Media<\/u>
\n
Marcy Nanus
Managing Partner, Trilon Advisors, LLC
mnanus@trilonadvisors.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WAYNE, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that its management team will present at the TD Cowen 45th\u00a0Annual Healthcare Conference on Tuesday March 4, 2025, at 2:30 p.m. ET. A live webcast of the presentation will be available on the\u00a0Events and Presentations\u00a0section of Palvella’s website at\u00a0www.palvellatx.com. An archived replay of the webcast will be available for approximately 90 days following the presentation. About Palvella Therapeutics Founded and led by rare drug disease drug development veterans, Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical … <\/p>\n

Continue reading “Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-817508","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPalvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WAYNE, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that its management team will present at the TD Cowen 45th\u00a0Annual Healthcare Conference on Tuesday March 4, 2025, at 2:30 p.m. ET. A live webcast of the presentation will be available on the\u00a0Events and Presentations\u00a0section of Palvella’s website at\u00a0www.palvellatx.com. An archived replay of the webcast will be available for approximately 90 days following the presentation. About Palvella Therapeutics Founded and led by rare drug disease drug development veterans, Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical … Continue reading "Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-25T13:16:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Mzg4OCM2Nzc2NDc3IzIxMjMxNjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference\",\"datePublished\":\"2025-02-25T13:16:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\\\/\"},\"wordCount\":291,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4Mzg4OCM2Nzc2NDc3IzIxMjMxNjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\\\/\",\"name\":\"Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4Mzg4OCM2Nzc2NDc3IzIxMjMxNjM=\",\"datePublished\":\"2025-02-25T13:16:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4Mzg4OCM2Nzc2NDc3IzIxMjMxNjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4Mzg4OCM2Nzc2NDc3IzIxMjMxNjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference - Market Newsdesk","og_description":"WAYNE, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that its management team will present at the TD Cowen 45th\u00a0Annual Healthcare Conference on Tuesday March 4, 2025, at 2:30 p.m. ET. A live webcast of the presentation will be available on the\u00a0Events and Presentations\u00a0section of Palvella’s website at\u00a0www.palvellatx.com. An archived replay of the webcast will be available for approximately 90 days following the presentation. About Palvella Therapeutics Founded and led by rare drug disease drug development veterans, Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical … Continue reading \"Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-25T13:16:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Mzg4OCM2Nzc2NDc3IzIxMjMxNjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference","datePublished":"2025-02-25T13:16:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\/"},"wordCount":291,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Mzg4OCM2Nzc2NDc3IzIxMjMxNjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\/","name":"Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Mzg4OCM2Nzc2NDc3IzIxMjMxNjM=","datePublished":"2025-02-25T13:16:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Mzg4OCM2Nzc2NDc3IzIxMjMxNjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4Mzg4OCM2Nzc2NDc3IzIxMjMxNjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/817508","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=817508"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/817508\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=817508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=817508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=817508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}